ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC

TARRYTOWN, N.Y. and PARIS , Sept. 19, 2021 /PRNewswire/ — Phase 3 trial met its primary and key secondary endpoints Libtayo is one of two PD-(L)1 inhibitors to demonstrate positive Phase 3 results in first-line advanced NSCLC irrespective of histology both as monotherapy and in combination with


Get every new post delivered right to your inbox.

Original Source